Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.57 |
| ▸ | JAK2 | O60674 | 9/20 | 0.44 |
| ▸ | JAK3 | P52333 | 8/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975575 | 1.00 | MTOR (0.57) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL974867 | 1.00 | MTOR (0.57) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL975085 | 0.92 | MAP3K11 (0.48) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL977189 | 0.92 | MAP3K11 (0.48) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL975086 | 0.92 | MAP3K11 (0.48) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL977378 | 0.88 | MTOR (0.56) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL976227 | 0.88 | MTOR (0.56) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL976224 | 0.88 | MTOR (0.56) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL977646 | 0.79 | MTOR (0.63) | MTORJAK2JAK3MAP3K11JAK1 | |
| SCHEMBL977287 | 0.79 | MTOR (0.59) | MTORJAK2JAK3MAP3K11JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | claimed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | claimed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2583970-B1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | CYTOKINETICS INC (US) | 2015-10-14 | — | — | EP | claimed |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2834269-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | Cytokinetics, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2013151938-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| EP-2069352-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2013-10-09 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| US-8299248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INCORPORATED (US) | 2012-10-30 | — | — | US | claimed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-8227603-B2 | Modulating skeletal muscle | CYTOKINETICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | claimed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | claimed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | MTOR 607/4885JAK2 3805/4885JAK3 3594/4885 |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | MTOR 4448/4885JAK2 4652/4885JAK3 4833/4885 |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, TNNT2 | MTOR 4845/4885JAK2 4792/4885JAK3 4778/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | MTOR 607/4885JAK2 3805/4885JAK3 3594/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | MTOR 3297/4885JAK2 717/4885JAK3 1563/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | MTOR 2781/4885JAK2 2337/4885JAK3 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.